

Ali McBride

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6907741/publications.pdf>

Version: 2024-02-01

112
papers

1,979
citations

293460

24
h-index

325983

40
g-index

112
all docs

112
docs citations

112
times ranked

3721
citing authors

#	ARTICLE	IF	CITATIONS
1	Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients. <i>Future Oncology</i> , 2022, 18, 363-373.	1.1	2
2	Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, 28, 390-400.	0.5	1
3	Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer. <i>Future Oncology</i> , 2022, 18, 2381-2390.	1.1	3
4	Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia. <i>Value in Health</i> , 2022, 25, 1685-1695.	0.1	6
5	National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association Survey. <i>JCO Oncology Practice</i> , 2022, 18, e1289-e1296.	1.4	10
6	Economic evaluations of adjunctive osimertinib treatment in surgically resected epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC): Analysis for stage 1B disease.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20502-e20502.	0.8	0
7	Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 658-672.	0.5	4
8	Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer. <i>Journal of Medical Economics</i> , 2021, 24, 743-756.	1.0	9
9	Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United States. <i>Journal of Medical Economics</i> , 2021, 24, 816-827.	1.0	3
10	Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER Medicare database. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862199127.	1.0	1
11	Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience. <i>Supportive Care in Cancer</i> , 2021, 29, 4867-4874.	1.0	8
12	Polatuzumab vedotin-bendamustine-rituximab (PBR) versus tafasitamab-lenalidomide (Tafal) in ASCT-transplant ineligible relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Economic evaluation including novel metrics.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19535-e19535.	0.8	0
13	Cost-efficiency analysis of conversion from reference pegfilgrastim to its biosimilar (pegfilgrastim-jmdb) and expanded access to food and transportation support for Medicare/Medicaid patients within the CMS Oncology Care Model.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18837-e18837.	0.8	3
14	Economic evaluation of six and 12 month (m) treatment with isatuximab and carfilzomib and dexamethasone (IKd) versus daratumumab and carfilzomib and dexamethasone (DKd) in patients with relapsed or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2021, 39, e20010-e20010.	0.8	2
15	Sustained response to pembrolizumab in recurrent perivascular epithelioid cell tumor with elevated expression of programmed death ligand: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 400.	0.4	4
16	Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017). <i>Annals of Hematology</i> , 2021, 100, 2501-2512.	0.8	13
17	Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma. <i>Leukemia Research</i> , 2021, 106, 106591.	0.4	7
18	Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer. <i>Future Oncology</i> , 2021, 17, 4561-4570.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework. <i>JCO Oncology Practice</i> , 2021, 17, e1139-e1149.	1.4	12
20	Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy. <i>Future Oncology</i> , 2021, 17, 3485-3497.	1.1	4
21	Institutional chart review on same-day pegfilgrastim administration in small cell lung cancer (SCLC) patients receiving myelotoxic chemotherapy. <i>Journal of Clinical Oncology</i> , 2021, 39, 71-71.	0.8	2
22	Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study. <i>Leukemia Research</i> , 2021, 111, 106671.	0.4	6
23	Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment. <i>Journal of Medical Economics</i> , 2021, 24, 598-606.	1.0	5
24	Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile. <i>Supportive Care in Cancer</i> , 2021, , 1.	1.0	4
25	Comparative Cost-Efficiency Analysis of Trilaciclib, a Novel CDK4/6 Inhibitor, in the Prophylaxis of Chemotherapy-Induced Myelosuppression. <i>Blood</i> , 2021, 138, 1907-1907.	0.6	1
26	Economic evaluation of polatuzumab-bendamustine-rituximab vs. tafasitamab-lenalidomide in transplant-ineligible R/R DLBCL. <i>Journal of Medical Economics</i> , 2021, 24, 14-24.	1.0	4
27	Transitioning Select Chemotherapeutics to the Outpatient Setting Improves Care and Reduces Costs. <i>Oncology Issues</i> , 2021, 36, 56-64.	0.0	0
28	Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e55-e64.	2.0	54
29	Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma. <i>Journal of Medical Economics</i> , 2020, 23, 28-36.	1.0	19
30	Revisiting Role of Vaccinations in Donors, Transplant Recipients, Immunocompromised Hosts, Travelers, and Household Contacts of Stem Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e38-e50.	2.0	7
31	Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv. <i>Journal of Medical Economics</i> , 2020, 23, 1466-1476.	1.0	15
32	Pricing methods in outcome-based contracting: 4: safety-based pricing. <i>Journal of Medical Economics</i> , 2020, 23, 1237-1245.	1.0	4
33	Pricing methods in outcome-based contracting: 5: risk of efficacy failure-based pricing. <i>Journal of Medical Economics</i> , 2020, 23, 1246-1255.	1.0	4
34	Pricing methods in outcome-based contracting: 1: cost effectiveness analysis and cost-utility analysis-based pricing. <i>Journal of Medical Economics</i> , 2020, 23, 1215-1222.	1.0	8
35	Pricing methods in outcome-based contracting: 2: willingness-to-pay-based pricing. <i>Journal of Medical Economics</i> , 2020, 23, 1223-1229.	1.0	7
36	Pricing methods in outcome-based contracting: 6: adherence-based pricing. <i>Journal of Medical Economics</i> , 2020, 23, 1256-1265.	1.0	4

#	ARTICLE	IF	CITATIONS
37	Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 \hat{I} 's). <i>Journal of Medical Economics</i> , 2020, 23, 1266-1272.	1.0	6
38	Pricing methods in outcome-based contracting: \hat{I} '3: reference-based pricing. <i>Journal of Medical Economics</i> , 2020, 23, 1230-1236.	1.0	9
39	Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution. <i>Annals of Pancreatic Cancer</i> , 2020, 3, 2-2.	1.2	1
40	Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim. <i>Journal of Medical Economics</i> , 2020, 23, 856-863.	1.0	17
41	Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 91.	1.3	112
42	Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 327-334.	1.0	13
43	A Comparison of Same Day Versus Next Day Administration of Pegfilgrastim in Lymphoma Patients Receiving CHOP Chemotherapy. <i>Blood</i> , 2020, 136, 11-11.	0.6	0
44	Conversion to Biosimilar Pegfilgrastim-Jmdb from Pegfilgrastim with on-Body Injector Device in Diffuse Large B-Cell Lymphoma: Simulation Modeling of Cost-Savings and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy Considering Device Failure Rate. <i>Blood</i> , 2020, 136, 22-22.	0.6	0
45	Economic Evaluation of Ibrutinib Versus Acalabrutinib Versus Zanubrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2020, 136, 9-10.	0.6	0
46	Retrospective Real-World Analysis of the Primary Safety Outcomes in Venous Thromboembolism of High-Risk Major Bleeding Cancer Patients Receiving Therapeutic Anticoagulation. <i>Blood</i> , 2020, 136, 15-16.	0.6	1
47	Simulation Modeling of Cost-Savings from Conversion to Biosimilar Pegfilgrastim-Cbqv for the Prophylaxis of Chemotherapy-Induced Neutropenia, and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy from Derived Cost-Savings in Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 24-25.	0.6	0
48	Impact of Treatment Sequencing on Outcomes and Costs in Relapsed Follicular or Other Low Grade B-Cell Non-Hodgkin Lymphoma - Results of an Evidence-Based Budget Impact Model. <i>Blood</i> , 2020, 136, 14-15.	0.6	0
49	A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI. <i>Supportive Care in Cancer</i> , 2019, 27, 873-878.	1.0	19
50	Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 16-25.	2.0	28
51	Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios inversely correlate to clinical and pathologic stage in patients with resectable pancreatic ductal adenocarcinoma. <i>Annals of Pancreatic Cancer</i> , 2019, 2, 8-8.	1.2	8
52	Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 1749-1752.	0.5	22
53	Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization. <i>Leukemia Research</i> , 2019, 85, 106215.	0.4	8
54	Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 583-592.	1.9	17

#	ARTICLE	IF	CITATIONS
55	The association of <i>BRCA1</i> and <i>BRCA2</i> mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. <i>Prostate</i> , 2019, 79, 880-895.	1.2	100
56	Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 397-405.	0.2	13
57	Response to Katona et al. <i>Journal of the National Cancer Institute</i> , 2019, 111, 524-525.	3.0	1
58	Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 137, 18-26.	2.0	12
59	Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review. <i>Immunotherapy</i> , 2019, 11, 373-378.	1.0	22
60	Chemotherapy Stewardship. <i>Oncology Issues</i> , 2019, 34, 3-3.	0.0	0
61	Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 94-99.	2.0	140
62	Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma. <i>JAMA Dermatology</i> , 2019, 155, 22.	2.0	25
63	Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting. <i>Blood</i> , 2019, 134, 2153-2153.	0.6	4
64	Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review. <i>Journal of Hematology (Brossard, Quebec)</i> , 2019, 8, 1-10.	0.4	5
65	Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 866-876.	0.8	13
66	Economic evaluation of anaplastic lymphoma kinase (ALK) inhibitors brigatinib, alectinib and crizotinib in non-small cell lung cancer (NSCLC): Analysis for intracranial metastasis-related progression free survival (CNSPFS).. <i>Journal of Clinical Oncology</i> , 2019, 37, e20515-e20515.	0.8	0
67	Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without <i>BRCA1</i> or <i>BRCA2</i> Mutations. <i>Journal of the Advanced Practitioner in Oncology</i> , 2019, 10, 428-439.	0.2	2
68	Healthcare Resource Utilization with Rasburicase in the Management of Patients with Tumor Lysis in the Outpatient Setting: Results from a Community Oncology Cohort. <i>Blood</i> , 2019, 134, 3401-3401.	0.6	0
69	Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 125, 1-11.	2.0	29
70	Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 186-200.	2.0	80
71	Emerging immune targets for the treatment of multiple myeloma. <i>Immunotherapy</i> , 2018, 10, 265-282.	1.0	19
72	Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer: a systematic review. <i>Bone Marrow Transplantation</i> , 2018, 53, 1242-1254.	1.3	6

#	ARTICLE	IF	CITATIONS
73	Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. <i>Journal of Medical Economics</i> , 2018, 21, 606-609.	1.0	8
74	Pentoxifylline and vitamin E drug compliance after adjuvant breast radiation therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 19-24.	0.6	15
75	BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1178-1189.	3.0	92
76	ASHP-HOPA guidelines on the roles and responsibilities of the pharmacy technician in ambulatory oncology pharmacy. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 1304-1311.	0.5	3
77	Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust. <i>Oncologist</i> , 2018, 23, 1188-1198.	1.9	34
78	Implementation of a pharmacy-managed program for the transition of chemotherapy to the outpatient setting. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, e246-e258.	0.5	14
79	Subcutaneous Versus Intravenous Rituximab in Non-Hodgkin Lymphoma Treated with R-CHOP: Economic Modeling for the US. <i>Blood</i> , 2018, 132, 4776-4776.	0.6	7
80	Efficacy and Tolerability of Daratumumab in Heavily Pretreated AL Amyloidosis: A Systematic Review. <i>Blood</i> , 2018, 132, 2025-2025.	0.6	2
81	Outcomes of pegfilgrastim (PFG) administration on the same day vs the day after chemotherapy (CTX) in the prophylaxis of chemotherapy-induced (Febrile) neutropenia (CIN/FN): Systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14510-e14510.	0.8	2
82	BRCA1 and BRCA2 gene mutations and colorectal cancer risk: Systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 605-605.	0.8	1
83	Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. <i>Immunotherapy</i> , 2017, 9, 123-130.	1.0	78
84	Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: A focus review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 8-17.	2.0	12
85	A Review of Autologous Stem Cell Transplantation in Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 217-226.	1.2	73
86	Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: Review and pooled analysis of observational studies. <i>Leukemia Research</i> , 2017, 57, 104-108.	0.4	9
87	Waldenström Macroglobulinemia: Review of Pathogenesis and Management. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 252-262.	0.2	38
88	Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer. <i>Journal of Medical Economics</i> , 2017, 20, 345-352.	1.0	25
89	Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 109, 42-50.	2.0	59
90	Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2017, 9, 979-993.	1.0	21

#	ARTICLE	IF	CITATIONS
91	Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. <i>Future Oncology</i> , 2017, 13, 2285-2295.	1.1	25
92	Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. <i>Journal of Medical Economics</i> , 2017, 20, 1083-1093.	1.0	30
93	Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1063-1072.	1.9	8
94	Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review. <i>Pharmacoeconomics</i> , 2017, 35, 83-95.	1.7	11
95	Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017, 8, 705-720.	0.2	8
96	Understanding the biosimilar approval and extrapolation process—A case study of an epoetin biosimilar. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 104, 98-107.	2.0	9
97	Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1182-1196.	2.0	6
98	Tocilizumab for steroid refractory acute graft-versus-host disease. <i>Leukemia and Lymphoma</i> , 2016, 57, 81-85.	0.6	35
99	A review in the treatment of oncologic emergencies. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 625-638.	0.5	26
100	Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation. <i>Clinical Case Reports (discontinued)</i> , 2015, 3, 728-730.	0.2	6
101	Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 353-360.	0.5	52
102	Evolving Biosimilars Marketplace. <i>Hospital Pharmacy</i> , 2014, 49, 1-5.	0.4	0
103	Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. <i>Supportive Care in Cancer</i> , 2014, 22, 2911-2916.	1.0	14
104	Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis. <i>American Health and Drug Benefits</i> , 2014, 7, 50-8.	0.5	10
105	National survey on the effect of oncology drug shortages on cancer care. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 609-617.	0.5	90
106	Comparative Evaluation of Single Fixed Dosing and Weight-Based Dosing of Rasburicase for Tumor Lysis Syndrome. <i>Pharmacotherapy</i> , 2013, 33, 295-303.	1.2	39
107	Tocilizumab In The Treatment Of Steroid Refractory Graft Versus Host Disease: A Single Institutional Experience. <i>Blood</i> , 2013, 122, 2067-2067.	0.6	2
108	Drug shortages in oncology. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 1190-1190.	0.5	3

#	ARTICLE	IF	CITATIONS
109	<i>Silybum marianum</i> (milk thistle) in the management and prevention of hepatotoxicity in a patient undergoing reinduction therapy for acute myelogenous leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2012, 18, 360-365.	0.5	19
110	Eribulin mesylate: A novel halichondrin B analogue for the treatment of metastatic breast cancer. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 745-755.	0.5	40
111	Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies. <i>Journal of Hematology and Oncology</i> , 2012, 5, 75.	6.9	65
112	Suspected Methotrexate Toxicity From Omeprazole. <i>Journal of Pharmacy Practice</i> , 2012, 25, 477-485.	0.5	16